Cogstate (ASX:CGS) Other Current Receivables: A$0.00 Mil (As of Dec. 2025)


ASX:CGS Cogstate Ltd ASX:CGS
77 GF Score
Price A$2.71
GF Value A$2.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cogstate Other Current Receivables?

Cogstate ASX:CGS +0.74% 77 Other Current Receivables is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CGS with a GF Score™ of 77/100 and a GF Value™ of A$2.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Cogstate's Other Current Receivables for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Cogstate's annual Other Current Receivables declined from Jun. 2023 (A$0.02 Mil) to Jun. 2024 (A$-0.03 Mil) but then increased from Jun. 2024 (A$-0.03 Mil) to Jun. 2025 (A$-0.03 Mil).

Cogstate Other Current Receivables Related Terms

Cogstate Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Cogstate's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogstate Other Current Receivables Chart

Cogstate Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.31 0.02 -0.03 -0.03

Cogstate Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.03 0.00 -0.03 0.00
ASX:CGS
77GF Score
Cogstate Ltd ASX:CGS
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogstate Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of A$0.00 Mil mean?
Cogstate (ASX:CGS) has a Other Current Receivables of A$0.00 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Cogstate and its competitors.
Is Cogstate's Other Current Receivables too high?
Cogstate's current Other Current Receivables is A$0.00 Mil. Overall, Cogstate has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's Other Current Receivables compare to VEEV and BTSG?
Cogstate's Other Current Receivables of A$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Healthcare Providers & Services company?
A good Other Current Receivables depends on the Healthcare Providers & Services industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Cogstate and its competitors. Cogstate's current Other Current Receivables is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (ASX:CGS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$2.06, compared to a current price of A$2.71 — trading 31.6% above its estimated fair value. The current Other Current Receivables is A$0.00 Mil. Cogstate's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Cogstate (ASX:CGS), the current Other Current Receivables is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cogstate (ASX:CGS) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of A$2.71 is trading 31.6% above its estimated GF Value™ of A$2.06. GuruFocus considers Cogstate to be Significantly Overvalued.

Key valuation signals for ASX:CGS:

  • Other Current Receivables: A$0.00 Mil
  • GF Value™: A$2.06 vs. price of A$2.71 (31.6% above fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cogstate Business Description

Other Exchanges COGZF:USAC4B:Germany
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
77GF Score

Get the complete analysis for ASX:CGS

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.71
Price
A$2.06
GF Value